Beef Producers Optimistic For Year Ahead

Feb 07, 2020

Manitoba Beef Producers (MBP) 41st Annual General Meeting wraps up Friday in Brandon.

Outgoing President Tom Teichroeb commented on the state of the industry.

"We have an incredible amount of potential here that we still need to realize," he said. "Certainly before we can realize that we have to catch up a little bit from the last two years with the drought and the different challenges that we've had. Overall, a tremendous amount of optimism from my perspective. On the national side we had one of our best years in trade and marketing our product abroad."

Teichroeb says one of the biggest challenges for the industry is passing the torch to the younger generation.

"To make sure there is succession in the industry. In agriculture in general, you will see that the majority of the producers are the more mature...generation and we're looking for more young folks to come into the industry...If we can find a way, through the industry and government together shaping policy so that it's favourable for those young producers to come in, then we have achieved a lot."

The theme of the AGM this year was "Where Beef Fits in an Evolving Marketplace".

Click here to see more...

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.